- Home
- BKYI vs XBIO Comparison
BKYI vs XBIO Comparison
Compare BKYI & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- XBIO
- Stock Information
- Founded
- BKYI 1993
- XBIO N/A
- Country
- BKYI United States
- XBIO United States
- Employees
- BKYI N/A
- XBIO N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- XBIO Health Care
- Exchange
- BKYI Nasdaq
- XBIO Nasdaq
- Market Cap
- BKYI 4.9M
- XBIO 4.2M
- IPO Year
- BKYI 1997
- XBIO N/A
- Fundamental
- Price
- BKYI $0.85
- XBIO $2.96
- Analyst Decision
- BKYI
- XBIO Hold
- Analyst Count
- BKYI 0
- XBIO 1
- Target Price
- BKYI N/A
- XBIO N/A
- AVG Volume (30 Days)
- BKYI 305.4K
- XBIO 6.9K
- Earning Date
- BKYI 05-15-2025
- XBIO 05-13-2025
- Dividend Yield
- BKYI N/A
- XBIO N/A
- EPS Growth
- BKYI N/A
- XBIO N/A
- EPS
- BKYI N/A
- XBIO N/A
- Revenue
- BKYI $6,355,527.00
- XBIO $2,582,728.00
- Revenue This Year
- BKYI $7.45
- XBIO $14.23
- Revenue Next Year
- BKYI $23.29
- XBIO $7.14
- P/E Ratio
- BKYI N/A
- XBIO N/A
- Revenue Growth
- BKYI N/A
- XBIO 5.63
- 52 Week Low
- BKYI $0.52
- XBIO $2.20
- 52 Week High
- BKYI $3.68
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- BKYI 57.19
- XBIO 48.28
- Support Level
- BKYI $0.80
- XBIO $2.85
- Resistance Level
- BKYI $0.92
- XBIO $3.22
- Average True Range (ATR)
- BKYI 0.08
- XBIO 0.14
- MACD
- BKYI 0.00
- XBIO -0.00
- Stochastic Oscillator
- BKYI 52.40
- XBIO 26.91
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.